PofoliaShared via Pofolia

International Journal of Oncology· 2018Q1· Review

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

Volker Schirrmacher

Short summary

Biological therapies, including immunotherapy and oncolytic virus (OV) therapy, demonstrate significantly lower side effects than traditional chemotherapy by specifically activating the immune system against cancer and leveraging innate defense mechanisms.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Biological therapies (immunotherapy, OV therapy) are better tolerated than chemotherapy.
  • Immunotherapies induce adaptive immunity with memory function.
  • Biological therapies specifically activate the immune system against cancer.
  • Type I interferon response from OVs is an innate immune defense mechanism.

AI-generated from the title and abstract; the full text is not read.

Abstract

The side effects of systemic chemotherapy used to treat cancer are often severe. For decades, oncologists have focused on treating the tumor, which may result in damage to the tumor‑bearing host and its immune system. Recently, much attention has been paid to the immune system of patients and its activation via biological therapies. Biological therapies, including immunotherapy and oncolytic virus (OV) therapy, are often more physiological and well tolerated. The present review elucidated how these therapies work and why these therapies may be better tolerated: i) In contrast to chemotherapy, immunotherapies induce a memory function of the adaptive immunity system; ii) immunotherapies aim to specifically activate the immune system against cancer; side effects are low due to immune tolerance mechanisms, which maintain the integrity of the body in the presence of B and T lymphocytes with their antigen‑receptor specificities and; iii) the type I interferon response, which is evoked by OVs, is an ancient innate immune defense system. Biological and physiological therapies, which support the immune system, may therefore benefit cancer treatment. The present review focused on immunotherapy, with the aim of reducing side effects and increasing long‑lasting efficacy in cancer therapy.

The authors' abstract, as published at the source. International Journal of Oncology, 2018 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Oncology

OncologyMedicine